Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech

Circulatory

  • 1
    News

    Predictors of ICH after thrombectomy identified

    April 30, 2020

    The sum of three variables may predict which patients undergoing thrombectomy up to 24 hours after a stroke are at higher risk of developing symptomatic intracranial hemorrhage.

  • 1
    News

    AUGUSTUS: After ACS or PCI, aspirin gives AFib patients scant benefit

    April 24, 2020

    Adding aspirin to an anticoagulant and P2Y12 inhibitor showed no net benefit, even acutely, suggesting need to target aspirin to highly selected patients.

  • 1
    News

    ACEI/ARBs linked with survival in hypertensive, Chinese COVID-19 patients

    April 22, 2020

    A study drawing from 1,128 hypertensive, Chinese patients with COVID-19 suggested that those on an ACEI or ARB had better 28-day survival.

  • News

    Mislabeled clopidogrel lot recalled, may contain simvastatin

    April 21, 2020

    International Laboratories has recalled one lot of clopidogrel tablets packaged in bottles of 30 tablets because it may contain simvastatin instead of clopidogrel.

  • 1
    News

    PCSK9 inhibitors unexpectedly link with lower VTE, aortic stenosis

    April 21, 2020

    Post hoc analyses of data from as many as 46,000 patients showed surprising links between PCSK9 inhibition and reduced rates of VTE and aortic stenosis.

  • News

    Larger absolute rivaroxaban benefit in diabetes: COMPASS

    March 29, 2020

    The new vascular low dose of rivaroxaban has had a slow start, but these results may stimulate use in patients with diabetes and stable disease.

  • 1
    News

    AUGUSTUS: Apixaban surpassed warfarin despite prior stroke or thromboembolism

    March 7, 2020

    LOS ANGELES – Secondary AUGUSTUS analysis showed ACS/PCI patients with AFib plus prior stroke, TIA, or thromboembolism did better on apixaban.

  • 1
    News

    AFib patients do best on a DOAC started 7-10 days post stroke

    March 4, 2020

    LOS ANGELES – Observational data hints at the best time to start oral anticoagulation in AFib patients after a cardioembolic stroke.

  • 1
    News

    What 2019’s top five CAD trials tell us

    January 29, 2020

    SNOWMASS, COLO. – Triple therapy as a triple threat – a three-pronged threat to patient safety, Dr. Malcolm R. Bell says.

  • 1
    News

    DOACs for treatment of cancer-associated venous thromboembolism

    January 23, 2020

    Recent studies suggest DOACs may be a viable option in the treatment of malignancy-associated VTE.

Previous1 … 7 8 9 10 11 … 25Next
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
fa-facebookfa-linkedinfa-instagramfa-youtube-playfa-commentfa-envelopefa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences